Syeda Kit
Product Images NDC 63629-2335

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Syeda (NDC 63629-2335). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (1e843fe7 6276 45a1 8a53 Bb12f40a3e05 01)

A horizontal forest plot depicting venous thromboembolism (VTE) risk with Drospirenone and Ethinyl Estradiol compared to LNG-containing combined oral contraceptives (COCs). The plot shows hazard, rate, or odds ratios from multiple studies, grouped into prospective cohort, retrospective cohort, case-control, and non-fatal idiopathic cases only, with confidence intervals depicted as horizontal lines intersecting risk estimates on a logarithmic scale from 0.1 to 10.*

FDA Label Image

Figure 2 (1e843fe7 6276 45a1 8a53 Bb12f40a3e05 02)

A horizontal bar chart titled 'Likelihood of Developing a VTE' showing the number of women with a blood clot out of 10,000 women years (WY) in four groups: Non-Pregnant Non-COC user (1 to 5), COC-User (3 to 9), Pregnancy (5 to 20), and Postpartum (12 weeks only) (40 to 65). The Pregnancy data note references an assumed pregnancy duration of nine months for rate calculation.*

FDA Label Image

Structure (1e843fe7 6276 45a1 8a53 Bb12f40a3e05 03)

Chemical structures of the active ingredients Drospirenone and Ethinyl Estradiol, shown as molecular diagrams with labeled atomic groups and bonds.*

FDA Label Image

Figure (1e843fe7 6276 45a1 8a53 Bb12f40a3e05 04)

An infographic illustrating pregnancy rates per 100 women per year by birth control method effectiveness. It lists methods from most effective with fewer than 1 pregnancy (implants, injections, intrauterine devices, sterilization), to moderate effectiveness (birth control pills, skin patch, vaginal ring with hormones), to less effective (condoms, diaphragm), to least effective approaches (no sex during fertile days, spermicide, withdrawal), and finally no birth control with 85 or more pregnancies. An arrow on the left indicates pregnancy frequency from fewer to more.*

FDA Label Image

Figure (1e843fe7 6276 45a1 8a53 Bb12f40a3e05 06)

A horizontal bar chart titled 'Likelihood of Developing a Serious Blood Clot' comparing four groups: Non-Pregnant Non-COC Users, COC-Users, Pregnant women, and Postpartum (12 weeks only) women. The chart displays the number of women with a blood clot out of 10,000 woman years, with ranges labeled for each group: 1 to 5, 3 to 9, 5 to 20, and 40 to 65 respectively. A footnote explains the pregnancy data is based on duration and reference studies.*

FDA Label Image

Label (Lbl636292335)

Label for Syeda (Drospirenone and Ethinyl Estradiol) tablets, USP, 3 mg/0.03 mg strength. The label indicates an 84 tablet kit containing three blister packs of 28 tablets each, with 21 yellow active tablets and 7 white inert tablets per blister pack. The labeler is Bryant Ranch Prepack, and the product is prescription only.*

FDA Label Image

Syeda (Syeda)

Blister pack for Syeda, containing Drospirenone and Ethinyl Estradiol tablets in a 3 mg/0.03 mg dosage. The pack is organized in a 4-week calendar format with days of the week labeled from Sunday to Saturday, guiding daily tablet intake. The label includes product name, active ingredients, and dosage strength.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.